United States: HIPAA/HITECH Omnibus Final Rule: Implications For Research

Last Updated: February 8 2013
Article by Robyn S. Shapiro and Julie Rusczek

The Department of Health and Human Services' HIPAA/HITECH Omnibus Final Rule (Final Rule) includes a number of provisions that will alleviate certain restrictions and administrative burdens in human subjects research and help streamline the documentation associated with research.  Here are the significant changes:

Compound Authorizations

The current HIPAA Privacy Rule generally prohibits "compound authorizations," which are authorizations for use and disclosure of protected health information (PHI) that are combined with any other legal permission.  An exception to this general prohibition permits combining an authorization for use and disclosure of protected health information in a research study with any other written permission for the same study, including an informed consent to participate in the research.  However, until March 26, 2013, the effective date of the Final Rule, even the same study exception is unavailable if one of the authorizations or permissions conditions treatment, payment, enrollment in a health plan or eligibility for benefits on the individual's provision of the authorization (a "conditioned authorization"), and the other authorization or permission does not contain such a condition (an "unconditioned authorization").  The purpose of this limitation on certain compound authorizations was to ensure that individuals could decline the activity described in the unconditioned authorization, yet still receive the treatment, services or benefits outlined in the conditioned authorization.  For example, research may include both treatment as part of the clinical trial and the banking of tissue and associated PHI.  The subject often must sign an authorization for use of his or her PHI in order to receive the research-related treatment (a "conditioned authorization"), but he or she is free to sign or to decide not to sign the tissue and data banking authorization ("unconditioned authorization").

Under the current HIPAA rule, a single authorization form cannot be used in this situation.  Instead, the covered entity must obtain two separate authorizations from research subjects:  one allowing use and disclosure of PHI to receive the research-related treatment and another allowing use and disclosure of PHI for the tissue and data banking.  Many researchers and research institutions expressed concerns about the additional paperwork and confusion that results from the separate form requirement.  In addition, they expressed concerns about the inconsistency of the current HIPAA rule with the Common Rule informed consent requirements (45 CFR Part 46) and with research documentation requirements outside the United States.

In response to these concerns, the Final Rule allows a covered entity to combine, in one form, conditioned and unconditioned authorizations for research,1 provided that the authorization clearly differentiates between the conditioned and unconditioned components and clearly allows the subject the option to participate in the unconditioned research activities.  These changes will allow covered entities to combine authorizations for use and disclosure of PHI for clinical trials and related tissue and data banking activities, as well as in other common research scenarios, such as a clinical trial involving an optional pharmacokinetics sub-study or a tissue banking protocol that permits future secondary research use of the data.

The Final Rule gives covered entities, researchers and institutional review boards discretion regarding how authorizations distinguish between conditioned and unconditioned activities.  In Commentary to the Final Rule, the Department of Health and Human Services (HHS) noted that a check-box or extra page explaining the "unconditioned" activity may be appropriate – but the Final Rule allows covered entities to determine the best approach.2

Authorization for Future Research Use and Disclosure

In the preamble to the Final Rule, HHS reversed its prior interpretation of the Privacy Rule that a research authorization must be study-specific and therefore may not include authorization for future research use.  As HHS explained, this interpretation was based on a concern that individuals would not have sufficient information to make truly informed decisions about the future research.  This interpretation, however, encumbered secondary research and diverged from Common Rule standards regarding subjects' informed consent for future research.

Under HHS's modified interpretation in the Final Rule, an authorization for the use or disclosure of PHI for research purposes does not have to be study-specific.  Rather, in order to satisfy the requirement that an authorization include a description of each purpose of the requested use or disclosure, an authorization for uses and disclosures of PHI for future research purposes must describe those purposes in a manner such that it would be reasonable for the individual to expect that his or her PHI could be used or disclosed for such future research.  The Final Rule gives covered entities, researchers, and IRBs flexibility to determine how to adequately describe the future research purpose, the information to be used or disclosed for the future research, and the recipients of the PHI for the future research.  In addition, HHS specifically noted that a description of the PHI to be used for the future research may include information collected beyond the time of the original study.  Finally, HHS stated that covered entities and researchers may rely on an IRB-approved consent obtained prior to the effective date of the Final Rule that reasonably informs individuals about future research, as long as the informed consent is combined with a HIPAA-compliant authorization.  HHS may issue additional guidance with respect to revocations of authorizations for future research uses.

Decedents' Protected Health Information

The Final Rule modifies the privacy protections applicable to decedents' health information.  Currently, the Privacy Rule requires covered entities to safeguard the privacy of a decedent's PHI indefinitely, in the same manner required for the PHI of living individuals.  If an authorization is required for a particular use or disclosure of PHI, the covered entity must obtain the authorization from the decedent's personal representative.  Under the Final Rule, any information that would otherwise constitute PHI of a decedent under 45 CFR § 160.201 ceases to be PHI 50 years after the death of the decedent.  This declassification will benefit research, as it can be burdensome to locate the personal representative of a decedent to obtain an authorization for use of the decedent's health information for research, especially if a significant period of time has passed since the individual's death.  HHS determined that 50 years is sufficient time to account for the privacy interests of living individuals related to the decedent.

Conclusions and Recommendations

The Final Rule provisions discussed above have important implications for research:

  • The changes concerning compound authorizations will alleviate administrative burdens on clinical trial subjects and researchers and facilitate harmonization with the Common Rule and global requirements for research documentation.
  • The revised interpretation regarding authorization for future research use will remove barriers on researchers' ability to use data for future research purposes – some of which cannot even be contemplated at the time the data is gathered, but which could hold great promise to advance science and medical care.
  • The declassification as "PHI" of certain information of decedents over time will ease researchers' ability to perform research using such information.

Researchers, research institutions and research sponsors have until September 23, 2013, to come into full compliance with the Final Rule.  In order to take advantage of the enhanced efficiencies in research initiatives that the Final Rule provides, however, those involved in research should begin revising research policies, procedures and forms now.  In addition, those involved in research should keep abreast of future regulatory developments and guidance on these and other issues, such as revocation of authorizations of use of PHI for future research use, additional guidance related to research use of genetic information, and harmonization of Final Rule provisions with FDA standards for informed consent.

Footnotes

1 This provision does not allow for the use of compound authorizations for research that involves the use or disclosure of psychotherapy notes.

2 The Commentary notes, however, that the Final Rule does not permit a combined authorization that allows the individual to opt out of the unconditioned research activities only (e.g., "check here if you do NOT want your data provided to the biospecimen bank."), because such an opt-out provision does not provide individuals a clear ability to authorize the optional research activity, and may be viewed as coercive.  Moreover, as HHS further explained, the Final Rule does not remove the requirement that an individual must affirmatively authorize the unconditioned research activities; it simply provides flexibility to streamline the authorization process by combining forms.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions